Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

164 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-16

Study Completion Date

2028-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods.

With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

NCT05941234

Glioblastoma, IDH-wildtype

RECRUITING NA

SIMPLIFication of Care Pathways for Patients with Rare Brain Tumors Through Artificial Intelligence

NCT06878469

Brain Tumors

RECRUITING NA

Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma

NCT05964569

Low Grade Glioma

RECRUITING PHASE2

Expert Consensus and Artificial Intelligence in Medical Decision Making in Patients with Malignant Brain Tumors

NCT06649591

Malignant Brain Tumors

ACTIVE_NOT_RECRUITING

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

NCT06492486

Diffuse Glioma Glioblastoma Adaptive Radiotherapy +1 more

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods.

With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with a histopathological diagnosis of glioma for whom it is possible to have cryopreserved or fixed in formalin and embedded in paraffin biological material. Specimens may result from incisional biopsy and/or surgical resection and/or blood. Whole blood is taken for germinal analysis;
2. Age \>=18 years;
3. Patients must understand and provide written informed consent;
4. Life expectancy \>3 months;
5. Presence of biological material from resection and blood considered sufficient by quality and quantity to proceed to molecular characterisation in the opinion of the Investigator Principal Investigator;
6. Presence of available and accessible clinical and histopathological data.

Exclusion Criteria

1. Refusal of informed consent;
2. Uncooperative patients;
3. Presence of other neoplastic diseases in the last 5 years;
4. Pregnant and/or breastfeeding women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No